HLHolger Lawall

Holger Lawall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Holger Lawall has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Peter Bramlage

    Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany

    5 shared publications
  • Berthold Amann

    Department of Internal Medicine, Franziskus Krankenhaus, Berlin Vascular Center, Berlin, Germany

    2 shared publications
  • C. Diehm

    SRH-Klinikum Karlsbad-Langensteinbach, Akademisches Lehrkrankenhaus der Universität Heidelberg

    2 shared publications
  • Curt Diehm

    Department of Internal Medicine/Vascular Medicine, Hospital Karlsbad-Langensteinbach, University of Heidelberg, Karlsbad, Germany

    2 shared publications
  • Alessandro Pira

    Department of Internal Medicine/Vascular Medicine, Hospital Karlsbad-Langensteinbach, Affiliated Teaching Hospital, University of Heidelberg, Karlsbad, Germany

    1 shared publication
  • Bernhard Angelkort

    Municipal Hospital Dortmund, Department of Medicine, Dortmund, Germany

    1 shared publication

Latest Publications

  • Zelltransplantation bei chronischer Extremitätenischämie

    by Berthold Amann, Holger Lawall, Claas Lüdemann

    Die autologe Stammzelltherapie ist nach den bislang vorliegenden Studien ein möglicher neuer Ansatz in der Behandlung der pAVK. Erste Erfahrungen zeigen eine gute Praktikabilität und sehr gute Sicherheit der Therapie. Die vorliegenden Ergebnisse der überwiegend unkontrollierten Studien zeugen von einer Verbesserung der Durchblutung, einhergehend mit klinischer Verbesserung. Eine erfolgreiche Umsetzung in die Praxis hängt von den Ergebnissen größerer kontrollierter Untersuchungen ab, die zurzeit laufen. Mit der Stimulation der Gefäßneubildung durch autologe Stammzellentransplantation ergeben sich in der Zukunft eventuell neue oder ergänzende Alternativen zu den bisherigen Konzepten der Behandlung der pAVK. Dies gilt vor allem für Patienten, bei denen eine progrediente Verschlechterung der Ischämie mit pharmakologischen Maßnahmen nicht verhindert werden kann und bei denen eine gefäßchirurgische oder interventionelle Revaskularisation nicht möglich ist. Die Erfahrungen der Autoren sind ermutigend; bei sorgfältiger Selektion der Patienten (erhaltungswürdige Extremität, noch messbare Restdurchblutung mit einem Knöchel-Arm-Index von mehr als 0,1 und einem transkutanen Sauerstoffpartialdruck von über 0 mmHg) ist die technisch dank der Automatisierung und der bettseitigen Durchführbarkeit einfach gewordene autologe Zelltherapie eine gute Möglichkeit, um Majoramputationen zu verhindern.

  • Stem cell and progenitor cell therapy in peripheral artery disease

    by Peter Bramlage, Berthold Amann, Holger Lawall

    Summary: Atherosclerotic peripheral artery disease (PAD) is a common manifestation of atherosclerosis. The occlusion of large limb arteries leads to ischaemia with claudication which can progress to critical limb ischaemia (CLI) with pain at rest, and to tissue loss. At present, common therapy for CLI is either surgical or endovascular revascularisation aimed at improving blood flow to the affected extremity. However, major amputation and death are still frequent complications. Exploring new strategies for revascularisation of ischaemic limbs is thus of major importance. Bone marrow (BM)-derived stem and progenitor cells have been identified as a potential new therapeutic option to induce therapeutic angiogenesis. Encouraging results of preclinical studies have rapidly led to several small clinical trials, in which BM-derived mononuclear cells were administered to patients with limb ischaemia. Clinical benefits were reported from these trials including improvement of ankle-brachial index (ABI), transcutaneous partial pressure of oxygen (TcPO2), re-duction of pain, and decreased need for amputation. Nonetheless, large randomised, placebo-controlled, double-blind studies are necessary and currently ongoing (BONMOT-CLI, JUVENTUS and NCT00498069). Further research relates to the optimal cell type and dosage, the isolation method, the role of colony-stimulating factors, administration route, and the supportive stimulation of cells with reduced functioning due to advanced PAD. Autologous stem cell therapy for ischaemic peripheral disease seems to be a promising new tool for the treatment of severe limb ischaemia. Preliminary evidence has established its safety, feasibility and effectiveness on several important endpoints. Several large endpoints studies are underway to further consolidate this evidence.


  • Long-term outcomes after medical and interventional therapy of critical limb ischemia

    by Holger Lawall, Hannah Gorriahn, Klaus Amendt, Jürgen Ranft, Peter Bramlage, Curt Diehm


  • Diabetisches Fußsyndrom

    by H. Lawall, H. Reike


    • 1 September 2008
      • Vol. 100  (3) , 475-82

    Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration.

    by Matthias Weck, Hannes Rietzsch, Holger Lawall, Uwe Pichlmeier, Peter Bramlage, Sebastian Schellong

    Patients with diabetic foot ulceration and critical limb ischemia have a high risk of major amputation, especially if limbs can not be revascularized. Urokinase is effective in improving microcirculation in critical limb ischemia and might improve outcomes. There are no data on the efficacy and safety of urokinase treatment (survival free of major amputation, ulcer healing and the rate of minor and major bleeding). Therefore, we aimed to investigate the effect of urokinase treatment in a phase II clinical trial. We performed an open, prospective, non-controlled, multicenter phase II cohort study in 77 type-2 diabetic patients with critical limb ischemia and diabetic foot ulceration. Patients had no surgical or endovascular treatment option based on interdisciplinary consensus. Urokinase (1 Mio IU if plasma fibrinogen >or=2.5 g/l, 0.5 Mio IU if fibrinogen <2.5 g/l) was administered for 21 days as an intravenous infusion over 30 minutes. Each patient was followed up for 12 months. Treatment for a median of 21 days resulted in 33% of patients being alive, having no major amputation and completely healed ulcers after 12 months. Total survival rate was 84.6%, amputation-free survival 69.2% and rate of major amputation 21.1%. Eighty-two percent of patients experienced at least once a complete ulcer healing within the course of study. Three serious adverse events were urokinase-related. Urokinase treatment in diabetic patients with critical limb ischemia appears to be effective, feasible and safe. Although this calls for a larger, randomized and controlled trial, the results are highly relevant for clinical practice to prevent these patients from receiving major amputation due to diabetic foot syndrome.


  • Angiologie

    by Holger Lawall, Curt Diehm

    The management of vascular disease has become more and more important due to increasing evidence of the extent of peripheral arterial disease in the population and venous thromboembolism in nonsurgical patients. The treatment not only includes the therapy of the cardiovascular risk factors and the application of platelet inhibitors but also the use of new drugs and new endovascular devices. Up till now it is still unclear whether the interventional therapy of carotid stenoses and the endovascular application of stent grafts in abdominal aortic aneurysm are superior to surgery. If the indication is given, hemodynamic renal artery stenoses should be treated by interventional procedures. The effect of medical prophylaxis of venous thromboembolism in nonsurgical patients is evident and proven by large studies. New anticoagulants enlarge the therapy of prophylaxis and treatment of venous thromboembolism.


  • Prevalence of deep vein thrombosis (DVT) in non-surgical patients at hospital admission

    by Wibke Hoffmanns, Phillip Hoffmanns, Uli Rapp, Michael Ames, Alessandro Pira, Dieter W. Paar, Peter Bramlage, Curt Diehm, Holger Lawall

    Summary: Venous thromboembolism (VTE) is known as a common complication in surgical and non-surgical patients. We hypothesized that according to the underlying risk factors and the acute illness, the prevalence of VTE in non-surgical patients admitted to hospital is widely underestimated. For three months each patient admitted to the department of internal medicine with an acute illness, but without known deep venous thrombosis (DVT) was investigated by ultrasound compression sonography. Patients’ history, risk factors and extent of immobilisation were documented. In patients with newly detected DVT D-dimer and fibrinogen were measured as well as computer tomography scans performed. Follow-up investigations of the DVT population were performed at four weeks and three months. Six hundred seventeen patients (49.3% men) were included. In 16 patients (men=7) a previously unknown thrombosis (2.6%) was detected, mainly in patients with acute cardio-pulmonary disease (56%) and the elderly (mean age 75.6 years). Eight patients had femoro-popliteal (50.0%), four a femoral (25.0%), and four a popliteal vein thrombosis (25.0%). Five had pulmonary embolism (31.3%). In patients with DVT D-dimer was 875 ± 1,228 mg/l, fibrinogen 568 ± 215 mg/dl and C-reactive-protein 58.54 ± 73.65 mg/dl. One patient died from sepsis during hospitalisation, one died from sudden cardiac death at home. None of the other 14 surviving patients relapsed. The study shows a 2.6% risk for DVT in outpatients with acute illness admitted to the department of internal medicine. These data demonstrate the high risk of DVT is in non-surgical patients. Early prophylaxis has to be considered in internal medicine patients especially in the elderly.